Description
Created On: 2020-07-15
Record Count: 20
Primary Industries
- Drugs
- Biotechnology
- Antibody
- Disease
- Cancer
- Cell Line
- Diagnostic
- DNA
- Vaccine
- Proteins
- Therapeutic
- Agriculture Forestry & Fishing
- Crop Production
- cell therapy
- Arthritis
- Drug Discovery
- Osteoarthritis
- Enzymes
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 28254
System means the Licensor's glutamine synthetase gene expression system consisting of the Cell Lines, the Vectors, and the System Know-How, whether used individually or in combination.
Subject Matter: Expression of polypeptides, such as antibodies, in myeloma cell lines
Title: Transformed Myeloma Cell-Line and a Process for the Expression of a Gene Coding for a Eukaryotic Polypeptide Employing Same
Subject Matter: GS Coding sequence
Title: Recombinant DNA which encodes glutamine synthetase
Subject Matter: Expression systems containing a hCMV promoter
Title: Recombinant DNA Expression Vectors
Subject Matter: Operation of glutamine synthetase expression systems in lymphoid cells
Title: Recombinant DNA Methods, Vectors and Host Cells
USA (cont I) 12.06.92 5879936 09.03.16
USA (cont II) 23.01.95 5891693 06.04.16
The Licensee will use the PRO 140 monoclonal antibody for treatment of HIV, after a recent study found that it suppressed the HIV virus in patients.
IPSCIO Record ID: 239013
5,981,216 – Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
5,770,359 – Recombinant DNA sequences, vectors containing them and method for the use thereof
5,827,739 – Recombinant DNA sequences, vectors containing them and method for the use thereof
5,591,639 – Recombinant DNA expression vectors
5,658,759 – Recombinant DNA expression vectors
Product means a monoclonal antibody to a bacterial cell surface adhesion known as Aurexis(TM) of which Licensee is the proprietor and which is obtained by the expression of any one gene or of any combination of genes by use of the Materials, or any formulation containing the same.
Intellectual Property means Materials Know-How and Patent Rights owned by Licensor or an Affiliate of Licensor and which Licensor has a right to grant herein.
Patent Rights means the patents and applications which Licensor has a right to grant herein short particulars of which are set out hereto and all patents and applications thereof of any kind throughout the world whether national or regional including but without prejudice to the generality of the foregoing, author certificates, inventor certificates, improvement patents, utility certificates and models and certificates of addition and including any divisions, renewals, continuations, continuations in part, extensions of reissue thereof.
Intellectual property and materials relating to the expression of recombinant monoclonal antibodies to bacterial surface proteins for use in the manufacture of Aurexis.
IPSCIO Record ID: 28224
(a) an exclusive license in the Territory under the Licensed Technology to conduct research on, develop and commercialize the Licensed Technology, to manufacture, have manufactured, use and have used, market, sell, have sold, offer for sale, have offered for sale, import and export and have imported and exported the compositions, technology or inventions, and to practice (or practise) the processes or methods that are within or that constitute the Licensed Technology for use in the Field.
(b) the right to grant Sublicenses (with the right of such sublicensees to grant further sublicenses).
Licensed Technology means Improvements, Inventions, Information and Know-How and Patents.
Patents means :
(a) (i) Patent number 5,767,336 granted in the United States of America entitled 'Gene Trap Vectors Comprising a Type II Transmembrane Domain', issued August 4,
1998;
(ii) Patent number 5,789,653 granted in the United States of America entitled 'Secretary Gene Trap', issued June 16, 1998;
(iii) Patent number 673,650 granted in Australia entitled 'Novel Vectors and Use Thereof for Capturing Target Genes', issued March 4, 1997
IPSCIO Record ID: 294014
Adeno-associated viruses are small viruses that infect humans and some other primate species. They belong to the genus Dependoparvovirus, which in turn belongs to the family Parvoviridae.
Cystic fibrosis is a hereditary disease that affects the lungs and digestive system. The body produces thick and sticky mucus that can clog the lungs and obstruct the pancreas. Cystic fibrosis (CF) can be life-threatening, and people with the condition tend to have a shorter-than-normal life span.
IPSCIO Record ID: 56588
7,012,172 VIRUS INDUCED GENE SILENCING IN PLANTS 3/14/2006
7,491,509 SYSTEM FOR EXPRESSION OF GENES IN PLANTS 2/17/2009
7,683,238 PRODUCTION OF PHARMACEUTICALLY ACTIVE PROTEINS IN SPROUTED SEEDLINGS 3/23/2010
7,692,063 PRODUCTION OF FOREIGN NUCLEIC ACIDS AND POLYPEPTIDES IN SPROUT SYSTEMS 4/6/2010
8,058,511 SYSTEM FOR EXPRESSION OF GENES IN PLANTS 11/15/2011
8,148,608 SYSTEMS AND METHODS FOR CLONAL EXPRESSION IN PLANTS 4/3/2012
8,173,408 RECOMBINANT CARRIER MOLECULE FOR EXPRESSION, DELIVERY AND PURIFICATION OF TARGET POLYPEPTIDES 5/8/2012
8,591,909 RECOMBINANT CARRIER MOLECULE FOR EXPRESSION, DELIVERY AND PURIFICATION OF TARGET POLYPEPTIDES 11/26/2013
8,597,942 SYSTEM FOR EXPRESSION OF GENES IN PLANTS 12/3/2013
8,951,791 SYSTEM FOR EXPRESSION OF GENES IN PLANTS 2/10/2015
9,012,199 RECOMBINANT CARRIER MOLECULE FOR EXPRESSION, DELIVERY AND PURIFICATION OF TARGET POLYPEPTIDES 4/21/2015
IPSCIO Record ID: 294297
Upon the Licensee exercising the Commercial License Option as provided in the Services Agreement, the Swiss Licensor grants to a non-exclusive license Under the Licensor Technology to propagate, have propagated, use, have used, import and have imported Cell Lines, develop, have developed make, have made, manufacture, have manufactured,_ to make, have .made; use, have used, offer for sale, have offered for sale, distribute for sale, have distributed_ for sale, sell, have sold, import, have Imported Products in the Licensed Field of Use, and otherwise exploit Products, lnciuding the use of products in clinical trials.
Cell Line shall mean a mammalian cell line.
The patents are Matrix attachment regions and methods for use thereof, and, High Efficiency. Gene Transfer and Expressions in Mammalian Cells by a Multiple Transfection Procedure of MAR sequences.
h16C3 is a humanized mAb that we believe recognizes TSAs from pancreatic/colorectal cancers and adenocarcinoma. This monoclonal antibody may increase diagnostic and therapeutic coverage for both colon and pancreatic cancer.
IPSCIO Record ID: 240466
– a non-exclusive world-wide license to exploit the Winter Patent commercially in any way whatsoever by the use of the Reshaping Process in the Fields and by the commercial exploitation in the Fields of any resulting antibodies provided always that any such exploitation does not involve the antibodies detailed.
– a non-exclusive sub-license under the Boss Patents to the extent required to enable the licensee to use the Reshaping Process to produce Products from mammalian cells and for no other purpose.
The Reshaping Process shall mean the genetic engineering of monoclonal antibodies comprising the replacement in whole or in part of the complementarity determining regions of one antibody by those of another as described in the Winter Patent.
The Products shall mean end products produced either directly or indirectly from antibodies which have been modified using the Reshaping Process and which are in a form capable of being marketed or sold upon a commercial basis.
Winter patents relate to Recombinant DNA products and Methods.
Boss patents relate to Multichain Polypeptides or Proteins and Processes for their Production Expression of multichain proteins, such as antibodies, in single hose cells.
IPSCIO Record ID: 212860
Licensor hereby grants Licensee an exclusive, royalty-free, fully paid-up, freely sublicensable and transferable, license under the Licensor Co-Formulation Patents for all uses and applications in the Field in the Territory, including to make, have made, use, sell, offer for sale, import, export, manufacture, develop and commercialize products for use in the Field and in the Territory.
Licensor hereby grants Licensee a non-exclusive, royalty-free, fully paid-up, freely sublicensable and transferable, license under the Licensor Vector Patents for all uses and applications in the Field in the Territory, including to make, have made, use, sell, offer for sale, import, export, manufacture, develop and commercialize products for use in the Field and in the Territory.
Licensor hereby grants Licensee an exclusive, royalty-free, fully paid-up, freely sublicensable and transferable, license to the Licensor BOT Know-How for all uses and applications in the Field in the Territory, including to make, have made, use, sell, offer for sale, import, export, manufacture, develop and commercialize products for use in the Field and in the Territory.
Licensor hereby grants Licensee a non-exclusive, royalty-free, fully paid-up, freely sublicensable and transferable, license to the Licensor General Know-How for all uses and applications in the Field in the Territory, including to make, have made, use, sell, offer for sale, import, export, manufacture, develop and commercialize products for use in the Field and in the Territory.
Co-Formulation Patents means those certain patents and patent applications as set forth, including all provisional applications, substitutions, continuations, continuations-in-part, divisions, renewals, all letters patent granted thereon, and all reissues, re-examinations and extensions thereof, and all foreign counterparts of any of the foregoing.
UCSF Licensed Patents means the patents and patent applications which are the subject of the Licensor License Agreements.
Vector Patents means those certain patents and patent applications set forth, including all provisional applications, substitutions, continuations, continuations-in-part, divisions, renewals, all letters patent granted thereon, and all reissues, re-examinations and extensions thereof, and all foreign counterparts of any of the foregoing.
BOT Know-How means all tangible and intangible techniques, information, technology, practices, trade secrets, inventions (other than those disclosed in a Licensor Patent), methods, processes, knowledge, know-how, conclusions, standard operating procedure, test data and results (including pharmacological, toxicological, manufacturing, and clinical test data and results), regulatory documentation, analytical and quality control data, and results or descriptions, in each case (i) owned or controlled by Seller or any of its Affiliates, and (ii) relating directly to the Products, as set forth under the heading, Licensor BOT Know-How. For the avoidance of doubt, Licensor BOT Know-How includes the Manufacturing Documentation.
General Know-How means all tangible and intangible techniques, information, technology, practices, trade secrets, inventions (other than those disclosed in a Licensor Patent), methods, processes, knowledge, know-how, conclusions, standard operating procedure, test data and results (including pharmacological, toxicological, manufacturing, and clinical test data and results), regulatory documentation, analytical and quality control data, and results or descriptions, in each case (i) owned or controlled by Seller or any of its Affiliates, and (ii) relating directly to the Products, as set forth, under the heading “General Know-How.â€
Co-Formulation Patents: Title: Antibody Co-formulations
Country
Application
File Date
Patent/Publication
US Provisional
61/240,155
9/4/2009
PCT
PCT/US10/47753
9/2/2010
WO 2011/028962 A2
US
12/875,083
9/2/2010
20110059079Â A1
US Con
14/705,713
5/6/2015
Europe
Co-Formulation Patents: Title: Anti-Botulism Antibody Coformulations
Country
Application
File Date
Patent/Publication
US Provisional
61/240,149
4/9/2009
PCT
PCT/US10/47752
9/2/2010
WO 2011/028961 A2
US
12/875,065
9/2/2010
8,821,879 B2
Vector Patents: Title: Methods and Materials for Transient Expressions of a Recombinant Protein
Country
Application
File Date
Patent/Publication
US Provisional
60/633,056
12/3/2004
PCT
PCT/US05/043922 2/5/2005
WO 2006/060769
US
11/831,691
7/31/2007
7,794,976 B2
Vector Patents: Title: Methods and Materials for Increasing Expression of Recombinant
Country
Application File Date
Patent/Publication
US Provisional
60/368,530
3/29/2002
PCT
PCT/US03/010154
3/31/2003
WO 04/033693
US
10,404,724
3/31/2003
7,192,737 B2
US
11/673,539
2/9/2007
7,993,915 B2
US
13/205,448
8/8/2011
8,497,096 B2
IPSCIO Record ID: 28035
IPSCIO Record ID: 202855
Licensees Licensed Product means any pharmaceutical formulation or product or method or system which contains an Anti-IgE Antibody.
Licensors Licensed Product means any pharmaceutical formulation or product or method or system which contains an Anti-IgE Antibody identified and synthesized by Licensor and/or a third party, or other IgE inhibiting antibodies within Licensorss MIGIS(R) program.
IPSCIO Record ID: 860
U.S. Patent No. 5,658,762, entitled “DNA molecules, expression vectors, and host cells expressing antigenized antibodies†issued April 19, 1997.
U.S. Patent Application No. 09/300,959, entitled “STI and related methods†pending.
IPSCIO Record ID: 121012
Licensees Licensed Product means any pharmaceutical formulation or product or method or system which contains an Anti-IgE Antibody.
Licensors Licensed Product means any pharmaceutical formulation or product or method or system which contains an Anti-IgE Antibody identified and synthesized by Licensor and/or a third party, or other IgE inhibiting antibodies within Licensorss MIGIS(R) program.
IPSCIO Record ID: 286023
The license s exclusive or non-exclusive on a patent by patent basis.
Licensed Product means any product that contains or comprises an Antibody, or any chemically modified Antibody, which recognizes TNF alpha. For the avoidance of doubt, Licensed Product shall not include non-Antibody inhibitors of TNF alpha.
The patents are titled Multichain Polypeptides or Proteins and Processes: for their Production;
Recombinant Antibody; Humanized Antibodies; Protein Expression System; Process for obtaining Antibodies; Monovalent Antibody Fragments; and, Biological Products.
IBD Indication means the prevention, treatment or control of Crohn’s Disease and/or ulcerative colitis in humans and/or animals.
RA Indication means the prevention, treatment or control of rheumatoid arthritis in humans.
IPSCIO Record ID: 3283
shall have the right to grant sublicenses consistent with this Agreement.
Diagnosis and classification of multiple myeloma
United States Patent 7,308,364
Diagnosis of multiple myeloma on gene expression profiling
IPSCIO Record ID: 26674
IPSCIO Record ID: 286057
Licensor shall create new Accepted Cell Lines based on RAGE-VT cell lines that Licensee proposes.
For the Research and Development License, and effective upon Licensors acceptance of a particular Accepted Cell Line, other than a Counterscreening Cell Line, Licensor grants to a non-exclusive, worldwide license, without the right to sublicense, under the Licensor Technology solely to use such Accepted Cell Line in the Field.
For the Evaluation License, as to each Collaboration Cell Line provided to Licensee by Licensor, Licensor grants a non-exclusive, worldwide license, without the right to sublicense, under the
Licensor Technology solely to conduct internal research evaluation of such Collaboration Cell Line.
For the Counterscreening License, and effective only upon Licensee s acceptance of a particular Accepted Cell Line that Licensee elected to be a Counterscreening Cell Line, Licensor grants to a non-exclusive, worldwide license, without the right to sublicense, under the Licensor Technology solely to use each such Counterscreening Cell Line for Counterscreening.
Product shall mean any product containing a Candidate Compound, including any formulation, dosage form, packaged form or delivery means thereof.
RAGE Technology shall mean any and all intellectual property, whether or not patentable, that is owned or licensed by Licensor and relates to Licensor techniques for activating gene expression, which are referred to by Licensor collectively as Random Activation of Gene Expression or RAGE technology.
Licensor is a functional genomics and biopharmaceutical company engaged in the development, application and commercialization of novel gene expression tools and therapeutic products.
IPSCIO Record ID: 26111
Licensor and Licensee are interested in collaborating in the start-up and initial operations of TIGM, including the endowment of TIGM with a library of such mouse embryonic stem cell clones containing gene trap mutations.
'Bioinformatics Software' means the software for the management and analysis of data relating to the OmniBank II Library and the production, genotyping and phenotypic analysis of knockout mice.
The Bioinformatics Software is an online analytical and decision-support system that catalogs the in vivo characterization of all mouse embryonic stem cell clones contained in the OmniBank II Library. Users can assess and search a wide range of phenotypic information at different levels, including raw data, calculated graphs with annotated summaries, and statistical analysis for selected diagnostic areas, by means of a standard web browser. Information can be retrieved through an intuitive search interface by gene description and sequence, disease indication, keywords, related publications and statistical significance.
'Materials' means Mutant Mice, Progeny and cells, tissues and other biological materials derived from any of the foregoing; provided that Materials shall not include cells, tissues or other biological materials that do not contain a Selected Mutation.
'Progeny' means mice, including successive generations thereof, that are produced, developed or derived by or on behalf of TIGM or Sublicensed Recipients directly or indirectly from a Mutant Mouse progenitor.
CRE-LOX PATENTS:
4,959,317
GENE TRAPPING PATENTS:
USA 6,136,566 10/24/00 10/4/2016
USA 6,207,371 3/27/01 10/4/2016
PCT PCT/US98/16373
USA 6,139,833 10/31/00 8/8/2017
PCT PCT/US99/06474
USA 6,080,576 6/27/00 4/8/2018
PCT PCT/US99/27366
USA 6,436,707 8/20/02 4/8/2018
USA 6,776,988 8/17/04 7/26/2019
USA 6,218,123 4/17/01 8/10/2019
USA 6,855,545 2/15/05 2/27/2017
USA 6,808,921 10/26/04 4/18/2018
IPSCIO Record ID: 227230
(i) a non-exclusive worldwide license to exploit the Winter Patent commercially in any way whatsoever by the use of the Reshaping Process in the Fields and by the commercial exploitation in the Fields of any resulting antibodies provided always that any such exploitation does not involve the antibodies detailed in the agreement hereto; and (ii) a non-exclusive sublicense under the Boss Patents to the extent required to enable the licensee to use the Reshaping Process in accordance with (i) above and for no other purpose.
The Licensee shall not be entitled to grant sublicenses of the rights granted to it under this Agreement except with the prior written consent of Licensor. The licensee shall use its best endeavors to ensure that any sublicensee performs its obligations under any such sublicense.
The Reshaping Process shall mean the genetic engineering of monoclonal antibodies comprising the replacement, in whole or in part, of the complementarity determining regions of one antibody by those of another as described in the Winter Patent.
The Boss Patents shall mean
(i) European Patent Application 0 120 693 (84301996.9) of 23 March 1984 naming Michael Alan Boss as an inventor;
(ii) GB Patent Application 8308235 of 25 March 1983;
(iii) Japanese Patent Application 501609/84 of 23 March 1984;
(iv) and any patent granted or to be granted on such patent application(s).
(v) US Patent 4 816 397 of 28 March 1989.
4,816,397 – Multichain polypeptides or proteins and processes for their production
The Products shall mean products produced either directly or indirectly from antibodies which have been modified using the Reshaping Process and which are in a form capable of being marketed or sold upon a commercial basis (the parties intend that the Products will include in some manner such an antibody).
License permits Licensee to humanize our murine monoclonal antibodies.
IPSCIO Record ID: 291138
Group 2 License Grant. University hereby grants to Licensee and the Covered Affiliates for the term of this Agreement the worldwide right and license, with the right to grant sublicenses, to develop, have developed, make, have made, use, have used, import, have imported, sell, offer for sale and have sold University Licensed Products under the Group 2 Patents in all fields of use. Such right and license shall be non-exclusive to Licensee in the LSD Field. Subject to this Agreement, such right and license shall be exclusive to Licensee outside the LSD Field.
University hereby grants to Licensee and the Covered Affiliates for the term of this Agreement the worldwide right and license, with the right to grant sublicenses, to develop, have developed, make, have made, use, have used, import, have imported, sell, offer for sale and have sold University Licensed Products under the Group 3 Patents in in all fields of use. Subject to this Agreement, such rights and license shall be exclusive to Licensee.
US 6,475,769 – Methods and cell line useful for production of recombinant adeno-associated viruses
US 7,238,526 – Methods and cell line useful for production of recombinant adeno-associated viruses
Group 2 Patents means the following patents:
US 6,759,237 – Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same
US 7,186,552 – Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same
Group 3 Patents means
US 7,056,502 – Recombinant aav vectors with AAV5 capsids and AAV5 vectors pseudotyped in heterologous capsids
University Licensed Product(s) means products that in the absence of this Agreement would, where and when made, used, sold, or imported, infringe at least one issued claim or pending claim of University Patent Rights; and products that are made using a process or machine that in the absence of this Agreement would, where and when used, infringe at least one issued claim or pending claim of University Patent Rights. All University Licensed Products intended to deliver the same Gene shall be considered a single University Licensed Product for purposes of this Agreement.
University Patent Rights means those patents and patent applications listed in this Agreement and all foreign counterparts thereof, as well as continuation, continuation-in-part, provided that such continuation-in-part relates directly to existing patents or patent applications and not to any new matter, divisional and re-issue applications
thereof, together with any and all patents issuing thereupon or upon any foreign counterparts thereof; provided, however, that Licensee acknowledge that the invention relating to non-invasive delivery of transgenes into the bloodstream, which is disclosed in Example 6 of International Patent Application No. PCT/USO1/13000 (M2304PCT), and in a US CIP application No. 09/955,444 (N2605), was made at University following termination of the research under the Sponsored Research Agreement. Licensee hereby acknowledge that they have no rights in this invention relating to non-invasive delivery of transgenes into the bloodstream, as defined in these applications and divisionals, continuations, re-examinations, re-issues, and any foreign counterparts thereof, and any patents issuing therefrom. Licensee agree that they will not make or pursue any claims that this invention as so defined is or should have been part of the University Patent Rights.
Gene means any nucleotide sequence that is capable of encoding, or of causing or modulating the expression of, a proteiin, protein fragment, or other genetic element. For the purposes hereof, a Gene having 90% homology to that of another Gene, and which expresses essentially the same protein for at least one biological function, shall be considered the same Gene as such other Gene.
LSD Field means the prevention, treatment, or cure of lysosomal storage diseases whether by in vivo or ex vivo means (together with preparation, research, development, and attempts to do the foregoing).
Cancer Field means the prevention, treatment or cure of malignancies whether by in vivo or ex vivo means together with preparation, research, development, and attempts to do the foregoing).
TNFr/Inflammatory Field means the prevention, treatment, or cure of any disease or diseases in whole or in part through use or delivery of the TNFr Gene or any other Gene acting in the Inflammatory Pathway, whether by in vivo or ex vivo means (together with preparation, research, development, and attempts to do the foregoing).
IPSCIO Record ID: 263903
This agreement includes non-exclusive grants back from Licensee to Licensor.
Amidating Enzyme means a recombinant enzyme used to convert non amidated peptides or proteins to amidated peptides or proteins.
Licensor sole improvements are Improved Bacterial Host Cell For the Direct Expression of Peptides; Recombinant Cell Lines Expressing Alpha-Amidating Enzyme; and, Improved Conditions For Amidation Of Peptides.
In organic chemistry, peptide synthesis is the production of peptides, compounds where multiple amino acids are linked via amide bonds, also known as peptide bonds. Peptides are chemically synthesized by the condensation reaction of the carboxyl group of one amino acid to the amino group of another.